07:24 AM EDT, 09/16/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Sunday that 10-year follow-up data from a phase 3 trial of Opdivo monotherapy and Opdivo in combination with Yervoy in advanced or metastatic melanoma showed continued long-term survival benefit.

The trial enrolled 945 patients with previously untreated advanced melanoma and after a minimum follow-up of 10 years, the median overall survival was 71.9 months for the combination therapy and 36.9 months for Opdivo, according to the statement.

"At 10 years, more than 40% of patients treated with Opdivo plus Yervoy were alive; a decade ago, this patient population faced a survival rate of around 25% after only one year," Bristol-Myers Squibb ( BMY ) said.

The company also said the Opdivo and Yervoy combination's safety profile remained consistent with earlier findings, with no new safety signals observed.

Price: 49.33, Change: +0.20, Percent Change: +0.41